Skip to main content

Table 4 Frequency of hypoglycemia among study groups

From: Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials

 

BMI <25 kg/m2

BMI 25–<30 kg/m2

BMI 30–<35 kg/m2

BMI ≥35 kg/m2

p value

Severe hypoglycemia, n (%)

1 (0.8)

2 (0.9)

0 (0.0)

2 (1.4)

0.54**

Events/patient-year mean (SD)

0.05 (0.6)

0.2 (3.5)

0.0 (0.0)

0.03 (0.3)

0.63*

Symptomatic hypoglycemiaa, n (%)

43 (32.3)

62 (27.9)

43 (25.9)

34 (24.1)

0.46**

Events/patient-year mean (SD)

2.2 (4.4)

2.1 (6.3)

1.8 (4.9)

1.6 (6.7)

0.81*

  1. SD standard deviation
  2. aRequiring blood glucose <60 mg/dL
  3. * Statistical significance of differences was determined by ANOVA
  4. ** Statistical significance of differences was determined by χ2 test
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us